NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults

NCT04516746

CompletedPhase 3

Sponsor: AstraZeneca

Conditions: COVID-19, SARS-CoV-2

Interventions: AZD1222, Placebo

Countries: United States, Chile, Peru

The aim of the study is to assess the safety, efficacy, and immunogenicity of AZD1222 for the prevention of COVID-19.

Eligibility overview

Sex: ALL

Age: 18 Years to 130 Years

Healthy volunteers: Yes

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Increased risk of SARS-CoV-2 infection
* Medically stable

Exclusion Criteria:

* confirmed or suspected immunosuppressive or immunodeficient state
* significant disease, disorder, or finding
* Prior or concomitant vaccine therapy for COVID-19

Locations (84)

Phoenix, Arizona, United States
Scottsdale, Arizona, United States
Little Rock, Arkansas, United States
Berkeley, California, United States
El Centro, California, United States
Los Angeles, California, United States
Los Angeles, California, United States
San Diego, California, United States
San Diego, California, United States
San Francisco, California, United States
San Francisco, California, United States
Torrance, California, United States
Denver, Colorado, United States
Danbury, Connecticut, United States
Coral Gables, Florida, United States
Lake Worth, Florida, United States
Miami Lakes, Florida, United States
Orlando, Florida, United States
Honolulu, Hawaii, United States
Meridian, Idaho, United States
Chicago, Illinois, United States
Indianapolis, Indiana, United States
Ankeny, Iowa, United States
Fairway, Kansas, United States
Kansas City, Kansas, United States
Wichita, Kansas, United States
Wichita, Kansas, United States
Lexington, Kentucky, United States
Lake Charles, Louisiana, United States
Monroe, Louisiana, United States
+ 54 more on CT.gov